PMID- 11801647
OWN - NLM
STAT- MEDLINE
DCOM- 20020212
LR  - 20190515
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 168
IP  - 3
DP  - 2002 Feb 1
TI  - Heparin induces differentiation of CD1a+ dendritic cells from monocytes: 
      phenotypic and functional characterization.
PG  - 1131-8
AB  - Dendritic cells (DCs) play important roles in initiation and regulation of immune 
      responses. DCs derived from human monocytes can be classified according to 
      presence of CD1a molecules. Although CD1a+ DCs can be prepared from monocytes in 
      media containing GM-CSF, IL-4, and FCS, it has been reported that CD1a+ DCs could 
      not be easily obtained from monocytes using media containing human serum or 
      plasma. In this study, we demonstrate for the first time that heparin can 
      reliably induce differentiation of CD1a+ DCs from monocytes with or without 
      autologous serum or plasma. The development of CD1a+ DCs is heparin concentration 
      dependent (0-50 U/ml). Comparing with CD1a- DCs developed without heparin, CD1a+ 
      DCs express higher CD40 and CD80 and lower CD86. Both CD1a+ and CD1a- DCs express 
      similar levels of HLA-DR. CD80, CD86, HLA-DR, and CD40 are proportionally 
      up-regulated when both types of DCs are stimulated with LPS or LPS plus 
      IFN-gamma. The effect of heparin is neutralized by heparin-binding proteins, such 
      as protamine sulfate, platelet factor-4, and beta-thromboglobulin. Functionally, 
      heparin-treated DCs respond to LPS or LPS plus IFN-gamma with higher IL-10 and 
      less IL-12 production than heparin-untreated DCs. Heparin-treated DCs are more 
      potent in priming allogeneic and autologous CD4+ T cells to proliferate and to 
      produce both type 1 and type 2 cytokines. The results of our study show that 
      CD1a+ DCs can be prepared from monocytes ex vivo without using xenogeneic serum 
      and may be used for immunotherapy.
FAU - Xia, Chang-Qing
AU  - Xia CQ
AD  - Department of Pathology, Immunology and Laboratory Medicine, University of 
      Florida, Gainesville, FL 32610, USA.
FAU - Kao, Kuo-Jang
AU  - Kao KJ
LA  - eng
GR  - HL-58809/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Antigens, CD1)
RN  - 0 (CD1a antigen)
RN  - 0 (Dextrans)
RN  - 0 (Growth Substances)
RN  - 0 (Heparin Antagonists)
RN  - 0 (Protamines)
RN  - 0 (fluorescein isothiocyanate dextran)
RN  - 130068-27-8 (Interleukin-10)
RN  - 187348-17-0 (Interleukin-12)
RN  - 9005-49-6 (Heparin)
RN  - I223NX31W9 (Fluorescein-5-isothiocyanate)
SB  - IM
MH  - Antigens, CD1/*biosynthesis
MH  - CD4-Positive T-Lymphocytes/drug effects/immunology
MH  - Cell Culture Techniques/methods
MH  - Cell Differentiation/drug effects/immunology
MH  - Cells, Cultured
MH  - Dendritic Cells/cytology/*drug effects/*immunology/metabolism
MH  - Dextrans/immunology/metabolism
MH  - Dose-Response Relationship, Immunologic
MH  - Fluorescein-5-isothiocyanate/*analogs & derivatives/metabolism
MH  - Growth Substances/blood/*pharmacology
MH  - Heparin/blood/*pharmacology
MH  - Heparin Antagonists/pharmacology
MH  - Humans
MH  - Immunophenotyping
MH  - Interleukin-10/metabolism
MH  - Interleukin-12/metabolism
MH  - Lymphocyte Activation/drug effects
MH  - Monocytes/*cytology/immunology
MH  - Phagocytosis/drug effects/immunology
MH  - Protamines/pharmacology
EDAT- 2002/01/22 10:00
MHDA- 2002/02/13 10:01
CRDT- 2002/01/22 10:00
PHST- 2002/01/22 10:00 [pubmed]
PHST- 2002/02/13 10:01 [medline]
PHST- 2002/01/22 10:00 [entrez]
AID - 10.4049/jimmunol.168.3.1131 [doi]
PST - ppublish
SO  - J Immunol. 2002 Feb 1;168(3):1131-8. doi: 10.4049/jimmunol.168.3.1131.